Home/ Crypto News/ Definium Therapeutics (DFTX) Stock Soars 20% on Successful Phase 3 Anxiety Trial Results

blockonomi 4 days ago

Definium Therapeutics (DFTX) Stock Soars 20% on Successful Phase 3 Anxiety Trial Results

Stocks

Definium Therapeutics (DFTX) stock rose 20% after DT120 ODT met Phase 3 endpoints for GAD treatment. NDA submission planned for H1 2027.

The post Definium Therapeutics (DFTX) Stock Soars 20% on Successful Phase 3 Anxiety Trial Results appeared first on Blockonomi.

Source: Source: Blockonomi